U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07014540) titled 'A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma' on June 03.
Brief Summary: To explore the efficacy and safety of irinotecan liposome injection combined with 5-FU/LV in the treatment of advanced neuroendocrine carcinoma (NEC)
Study Start Date: June 20
Study Type: INTERVENTIONAL
Condition:
Neuroendocrine Carcinomas (NEC)
Intervention:
DRUG: Irinotecan Hydrochloride Liposome Injection
Liposome irinotecan (70/50mg/m^2) will be administered by intravenous infusion on day 1 in a 2-week
DRUG: 5-FU
5-FU (2400mg/m^2) will be administered by continuous infusion for 46 hours in a 2-week
DRUG: LV
LV (400mg/m^2) w...